← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc.
$166,960,005
Total funding
83
Grants
Funding over time
peak $86.1M · FY2008–25$100M$75M$50M$25M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$166,960,005 · 83
By mechanism
—$166,960,005 · 83
Investigators at H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
NATIONAL FUNCTIONAL GENOMICS CENTER$70,483,722
· FY2008 · Department of Defense
USING COMBINATORIAL THERAPIES WITH DENDRITIC CELL THERAPIES TO IMPROVE SURVIVAL AND PREVENT RECURRENCE OF BREAST CANCER LEPTOMENINGEAL DISEASE (LMD)$18,696,738
· FY2025 · Defense Health Agency
NATIONAL FUNCTIONAL GENOMICS CENTER$14,504,704
· FY2008 · Department of Defense
CORRECTING THE ANTI-HER-2 CD4 TH1 RESPONSE IN BREAST CANCER THERAPY TO PREVENT RECURRENCE$10,850,836
· FY2016 · Defense Health Agency
NOVEL IMMUNOTHERAPY FOR BRAIN-METASTATIC BREAST CANCER$8,318,389
· FY2019 · Defense Health Agency
IMPACT OF TERTIARY LYMPHOID STRUCTURES (TLSS) IN ONCOLYTIC VIRUS-INDUCED TUMOR ELIMINATION$1,685,000
· FY2025 · Defense Health Agency
DEVELOPMENT OF ADOPTIVE T-CELL THERAPY IN BLADDER CANCER INCORPORATING PATIENT-SPECIFIC TUMOR MICROENVIRONMENT$1,657,861
· FY2022 · Department of the Army
CHARACTERIZE THE IMMUNE-ONCOLOGIC PROFILE OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN AND DEVELOP NEW THERAPEUTIC AVENUES FOR THIS PATIENT POPULATION$1,651,794
· FY2019 · Defense Health Agency
DYNAMIC: DEVELOPMENT OF A BEHAVIORAL INTERVENTION FOR YOUNG ADULTS WITH ADVANCED CANCER$1,619,065
· FY2025 · Defense Health Agency
HARNESSING CDK12 INHIBITION FOR THE TREATMENT OF HER2 BRAIN METASTATIC BREAST CANCERS$1,277,567
· FY2022 · Defense Health Agency
HARNESSING CDK12 INHIBITION FOR THE TREATMENT OF HER2+ BRAIN METASTATIC BREAST CANCERS$1,219,932
· FY2022 · Defense Health Agency
DEVELOPMENT OF ADOPTIVE T-CELL THERAPY IN BLADDER CANCER INCORPORATING PATIENT-SPECIFIC TUMOR MICROENVIRONMENT$1,193,945
· FY2022 · Department of the Army
CHARACTERIZATION OF PLANT-BASED PHENOLIC ALKANONES AS NEXT-GENERATION SUN PROTECTANTS FOR SKIN CANCER PREVENTION$1,187,274
· FY2024 · Defense Health Agency
CHARACTERIZING THE ROLE OF ABERRANT FGD1 SPLICING IN BRAIN AND BONE METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA$1,124,896
· FY2025 · Defense Health Agency
A PRESURGICAL WINDOW-OF-OPPORTUNITY TRIAL OF THE EFFECT OF ASPIRIN ON IMMUNOLOGICAL FEATURES OF OVARIAN TUMORS$1,120,216
· FY2020 · Defense Health Agency
THE ROLE OF HYPOXIA ON TUMOR-INFILTRATING LYMPHOCYTES (TIL) FROM RENAL CELL CARCINOMA (RCC)$1,004,589
· FY2022 · Defense Health Agency
PEER REVIEWED CANCER RESEARCH PROGRAM TRANSLATIONAL TEAM SCIENCE AWARD$995,267
· FY2025 · Defense Health Agency
IDENTIFICATION AND ASSESSMENT OF TARGETS FOR IMMUNOTHERAPY IN NF2-ASSOCIATED SCHWANNOMATOSIS$968,875
· FY2025 · Defense Health Agency
MESENCHYMAL STEM CELL CONTROL OF METASTATIC PROSTATE CANCER CELL EVOLUTION AND THERAPY RESISTANCE IN THE BONE MICROENVIRONMENT$943,436
· FY2018 · Defense Health Agency
CHARACTERIZATION OF PLANT-BASED PHENOLIC ALKANONES AS NEXT-GENERATION SUN PROTECTANTS FOR SKIN CANCER PREVENTION$918,976
· FY2024 · Defense Health Agency